A Randomized, Double-blind, Placebo-controlled Study of the Dosaging of AMPLIGEN 'Registered trade mark' (POLY I: POLY C12U), an Immunostimulant, in Conjunction With Influenza Vaccination

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Dosaging of AMPLIGEN 'Registered trade mark' (POLY I: POLY C12U), an Immunostimulant, in Conjunction With Influenza Vaccination

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Influenza virus vaccine; Rintatolimod
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Hemispherx Biopharma
  • Most Recent Events

    • 05 Feb 2009 Status changed from active, no longer recruiting to completed according to the Australian New Zealand Clinical Trials Registry record.
    • 05 Feb 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry record).
    • 02 Jun 2008 Status changed from initiated to in progress according to Hemispherx Biopharma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top